FindTrial
Sign In

A randomized, double-blind, Phase II/III study of JR-013 in the patients with renal anemia receiving hemodialysis treatment

A randomized, double-blind, Phase II/III study of JR-013 in the patients with renal anemia receiving hemodialysis treatment

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220475
Enrollment
Unknown
Registered
2007-12-03
Start date
2007-12-03
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia

Interventions

investigational material(s) Generic name etc : JR-013 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigation

Sponsors

KISSEI PHARMACEUTICAL CO.,LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 20 Years and above, Renal anemia patients receiving hemodialysis treatment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy and Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026